Organization (Academic)
Addis Ababa University
ClinicalTrials.gov lists Addis Ababa University as lead sponsor of 20 trials, counting the companies grouped under it. Addis Ababa University itself has 1 active development program and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 6 in 2026 and about 7 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Addis Ababa University and 1 company grouped under it: 20 lead-sponsored trials (19 its own, 1 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Ethiopian Institute of Water Resources | 1 | 1 |
Disease areas (54)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Anemia | 7 |
| Malnutrition | 5 |
| Tuberculosis | 5 |
| HIV Infections | 4 |
| Leishmaniasis, Visceral | 4 |
Showing 5 of 54 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 4 |
| 2024 | 8 |
| 2023 | 7 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 6 |
| 2017 | 1 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| CURCUMIN | Uterine Cervical Neoplasms | Not reported | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| MINOCYCLINE | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 3 hit target (n=3) | 1 of 3 on time (n=3) |
Journals published in (120)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| PloS one | 8 |
| Trials | 8 |
| BMJ open | 6 |
| Lancet (London, England) | 5 |
| PLoS neglected tropical diseases | 4 |
Showing 5 of 120 journals.
Financing and grant events (10)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-05-26 | NIH grant | 249,783 | Reporter |
| 2025-03-18 | NIH grant | 298,123 | Reporter |
| 2024-08-30 | NIH grant | 382,591 | Reporter |
| 2023-03-07 | NIH grant | 298,123 | Reporter |
| 2022-08-20 | NIH grant | 647,999 | Reporter |
Showing 5 of 10 events.
Organization relationships (26)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Armauer Hansen Research Institute, Ethiopia | Co sponsors trial with | 5 |
| Institute of Tropical Medicine, Belgium | Co sponsors trial with | 3 |
| University of Gondar | Co sponsors trial with | 3 |
| Karolinska Institutet | Co sponsors trial with | 3 |
| Drugs for Neglected Diseases | Co sponsors trial with | 3 |
Showing 5 of 26 relationships.
Latest dated events (72)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 72 events.
Biomarker capability evidence (24)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BLVRB | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CYP19A1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 24 evidence rows.
Biomarkers this organization publishes on (163)
Shown in this order: most publications first.
Showing 5 of 163 biomarkers.
On Scientist.com
Addis Ababa University is listed as a research supplier in the Scientist.com network.
- Website
- www.aau.edu.et
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Addis Ababa University on Scientist.com
For prices, more details, or to contact Addis Ababa University, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.